The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Toxicity and efficacy of bolus (BOL) versus continuous intravenous (CIV) dosing of doxorubicin (DOX) in soft tissue sarcoma (STS): Post hoc analysis of a prospective randomized trial.
 
Lee D. Cranmer
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Merck
Research Funding - Amgen; Bristol-Myers Squibb; CytRx Corporation; GlaxoSmithKline; Merck; Prometheus; Threshold Pharmaceuticals
 
Yao Lu
No Relationships to Disclose
 
Karla V. Ballman
Consulting or Advisory Role - ARIAD; Hospira
Patents, Royalties, Other Intellectual Property - Immune enrichment signature for response to trastuzumab in HER2+ breast cancer (Inst); Prostate cancer signature patent (Inst)
 
Elizabeth Trice Loggers
Research Funding - Daiichi Sankyo (Inst)
 
Seth Pollack
Consulting or Advisory Role - Amgen; Lilly; Nektar
Research Funding - Immune Design; Lilly/ImClone
Travel, Accommodations, Expenses - Lilly/ImClone